- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00767000
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
February 2, 2015 updated by: Merck Sharp & Dohme LLC
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus.
The primary hypotheses of this study are that treatment with MK-0941 added to insulin will provide greater reduction in hemoglobin A1c (HbA1c) level than will placebo added to insulin at 14 weeks, and that MK-0941 will be well-tolerated at 1 or more doses that demonstrate efficacy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This study is a 54-week randomized, double-blind base study with an optional 104-week extension study (MK-0941-007-11).
Beginning on Week 16, participants not randomized to the maximum dose of MK-0941 could up-titrate to MK-0941 40 mg three times daily.
Participants who complete the 54-week base study are eligible to enter the extension study and will remain in the treatment group to which they were assigned in the base study.
Study Type
Interventional
Enrollment (Actual)
813
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- has type 2 diabetes mellitus
- has body mass index >20 and <43 kg/m^2
- is a male, or a female who is unlikely to conceive
- currently on a stable dose of insulin with or without metformin for Type 2 diabetes mellitus
Extension Study Inclusion Criteria:
- completed the base study either on double-blind study medication or as part of the post-treatment follow up population
- had ≥85% compliance with double-blind and open-label medication during the base study double-blind treatment period
Exclusion Criteria:
- has any history of Type 1 diabetes mellitus or ketoacidosis
- has received more that 1 week of thiazolidinedione (such as pioglitazone or rosiglitazone) therapy or injectable increatin-based therapy (such as Byetta) within the prior 8 weeks
- has had ≥2 episodes during their lifetime or >1 episode within the past year resulting in hypoglycemic seizures, comas, or unconsciousness
- is on a weight loss program and is not in the maintenance phase, or patient is taking a weight loss medication (e.g., orlistat, sibutramine, rimonabant) within 8 weeks of Visit 1
- has undergone surgery within 30 days prior to Visit 1 or has planned major surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Lantus injection once daily
Other Names:
Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study.
The number of randomized participants who receive metformin will be capped at 70% of enrollment.
Matching placebo to MK-0941 three times daily
|
Experimental: MK-0941 10 mg
|
MK-0941 tablets three times daily
Lantus injection once daily
Other Names:
Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study.
The number of randomized participants who receive metformin will be capped at 70% of enrollment.
|
Experimental: MK-0941 20 mg
|
MK-0941 tablets three times daily
Lantus injection once daily
Other Names:
Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study.
The number of randomized participants who receive metformin will be capped at 70% of enrollment.
|
Experimental: MK-0941 30 mg
|
MK-0941 tablets three times daily
Lantus injection once daily
Other Names:
Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study.
The number of randomized participants who receive metformin will be capped at 70% of enrollment.
|
Experimental: MK-0941 40 mg
|
MK-0941 tablets three times daily
Lantus injection once daily
Other Names:
Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study.
The number of randomized participants who receive metformin will be capped at 70% of enrollment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hemoglobin A1c (HbA1c) Level
Time Frame: Baseline and Weeks 14, 54, 106, and 158
|
Least square means change from baseline in HbA1c.
HbA1c represents the percentage of glycated hemoglobin.
A negative number means reduction in HbA1c level.
|
Baseline and Weeks 14, 54, 106, and 158
|
Percentage of Participants Who Experienced at Least One Adverse Event
Time Frame: Entire study including 54-week study and 104-week extension
|
Entire study including 54-week study and 104-week extension
|
|
Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event
Time Frame: Entire study including 54-week study and 104-week extension
|
Entire study including 54-week study and 104-week extension
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Two-hour Post Meal Glucose Level
Time Frame: Baseline and Weeks 14, 54, 106, and 158
|
Least squares mean change from baseline in 2-hour post meal glucose level.
|
Baseline and Weeks 14, 54, 106, and 158
|
Change in the Fasting Plasma Glucose Level
Time Frame: Baseline and Weeks 14, 54, 106, and 158
|
Least squares mean change from baseline in fasting plasma glucose.
|
Baseline and Weeks 14, 54, 106, and 158
|
Percentage of Participants Who Achieve an HbA1c of <7.0%
Time Frame: Weeks 106 and 158
|
Weeks 106 and 158
|
|
Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%
Time Frame: Weeks 54, 106 and 158
|
Weeks 54, 106 and 158
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
October 3, 2008
First Submitted That Met QC Criteria
October 3, 2008
First Posted (Estimate)
October 6, 2008
Study Record Updates
Last Update Posted (Estimate)
February 19, 2015
Last Update Submitted That Met QC Criteria
February 2, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0941-007
- 2008_557
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on MK-0941
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Non-Insulin-Dependent
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes
-
Lupin Research IncCompletedBacterial VaginosesUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus
-
Genentech, Inc.Completed